Task Group Charge
To identify factors contributing to variation in access to and delivery of recommended lung nodule management, staging, and receipt of curative-intent surgery and radiation/SBRT for early-stage NSCLC, access to and use of comphrehensive biomarker testing for targeted therapies, and strategies to overcome the factors contributing to this variation.
Leadership
Gerard A. Silvestri, MD, MS
Task Group Chair
Steering Committee Member
Medical University of South Carolina
Douglas E. Wood, MD
Task Group Vice Chair
Vice Chair of NLCRT
University of Washington
Farhood Farjah, MD, MPH
Task Group Vice Chair
University of Washington
Task Group Members
Upal Basu Roy, PhD, MPH
LUNGevity Foundation
Vickie Beckler, MBA, RN
Medtronic
Thomas D’Amico, MD
Duke Cancer Institute
Megan Daly, MD
UC Davis Comprehensive Cancer Center
Elizabeth David, MD, MAS
University of Southern California
Frank Detterbeck, MD
Yale Cancer Center
Jan Eberth, PhD, MSPH
University of South Carolina
Louise M. Henderson, PhD, MSPH
University of North Carolina at Chapel Hill
James Jett, MD
National Jewish Health
Ella Kazerooni, MD, MS*
University of Michigan
Edward Kim, MD
Levine Cancer Institute
Jennifer King, PhD
GO2 Foundation for Lung Cancer
Amanda Kramar
Association of Community Cancer Centers
Christopher Lathan, MD, MS, MPH
Dana-Farber Medical Institute at St. Elizabeth’s Medical Center
Linda Martin, MD, MPH
University of Virginia
Nikki Martin, MA
LUNGevity Foundation
Renato Martins, MD, MPH
University of Washington
Amy Moore, PhD
GO2 Foundation for Lung Cancer
Benjamin Movsas, MD
Henry Ford Health System
Gregory Riely, MD, PhD
Memorial Sloan Kettering Cancer Center
M. Patricia Rivera, MD
University of North Carolina at Chapel Hill
Albert Rizzo, MD
American Lung Association
Liora Sahar, PhD, GISP
American Cancer Society
Robert Suh, MD
University of California, Los Angeles
William Travis, MD
Memorial Sloan Kettering Cancer Center
(*) indicates Steering Committee member
Opportunities For Intervention/Influence:
- Address the lack of experience and/or expertise in screen-detected lung nodule management
- Identify strategies to reduce the variation (geographic, SES, income, race/ethnicity, rural, etc.) in access to lung cancer specialists
- Identify strategies to overcome the non-adherence with staging and management guidelines
- Highlight the disparities in receipt of curative-intent surgery for early stage NSCLC and develop strategies to eliminate these disparities
- Develop strategies to reduce the variability in access and use of comprehensive biomarker testing for expression of immune-markers and targeted therapy